Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

S Sharmin; M Lefort; JB Andersen; E Leray; D Horakova; EK Havrdova; R Alroughani; G Izquierdo; S Ozakbas; F Patti; M Onofrj; A Lugaresi; M Terzi; P Grammond; F Grand’Maison; B Yamout; A Prat; M Girard; P Duquette; C Boz; M Trojano; P McCombe; M Slee; J Lechner-Scott; R Turkoglu; P Sola; D Ferraro; F Granella; J Prevost; D Maimone; O Skibina; K Buzzard; A Van der Walt; B Van Wijmeersch; T Csepany; D Spitaleri; S Vucic; R Casey; M Debouverie; G Edan; J Ciron; A Ruet; J De Sèze; E Maillart; H Zephir; P Labauge; G Defer; C Lebrun-Frénay; T Moreau; E Berger; P Clavelou; J Pelletier; B Stankoff; O Gout; E Thouvenot; O Heinzlef; A Al-Khedr; B Bourre; O Casez; P Cabre; A Montcuquet; A Wahab; JP Camdessanché; A Maurousset; I Patry; K Hankiewicz; C Pottier; N Maubeuge; C Labeyrie; C Nifle; D Laplaud; N Koch-Henriksen; FT Sellebjerg; PS Soerensen; CC Pfleger; PV Rasmussen; MB Jensen; JL Frederiksen; S Bramow; HK Mathiesen; KI Schreiber; M Magyari; S Vukusic; H Butzkueven; T Kalincik

Journal article

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

S Sharmin, M Lefort, JB Andersen, E Leray, D Horakova, EK Havrdova, R Alroughani, G Izquierdo, S Ozakbas, F Patti, M Onofrj, A Lugaresi, M Terzi, P Grammond, F Grand’Maison, B Yamout, A Prat, M Girard, P Duquette, C Boz Show all

CNS Drugs | ADIS INT LTD | Published : 2021

DOI: 10.1007/s40263-021-00860-7

Abstract

Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest. Methods: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients’ sex, age, disease duration, Expanded Disability St..

View full abstract

University of Melbourne Researchers

Sifat Sharmin Author

Tomas Kalincik Author

Related Projects (2)

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

BIOMARKERS TO PREVENT DISABILITY IN MULTIPLE SCLEROSIS

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

Grants

Awarded by Bayer

Funding Acknowledgements

The Clinical Outcomes Research unit at the University of Melbourne received funding from the National Health and Medical Research Council (Grant numbers 1140766, 1129789, and 1157717) to support this study. The MSBase Foundation is a not-for-profit organization that receives support from Merck, Biogen, Novartis, Roche, Bayer Schering, Sanofi Genzyme, and Teva Pharmaeutical Industries. OFSEP was supported by a grant provided by the French State and handled by the "Agence Nationale de la Recherche," within the framework of the " Investments for the Future" program, under the reference ANR-10COHO-002, by the Eugene Devic EDMUS Foundation against multiple sclerosis and by the ARSEP Foundation. The Danish Multiple Sclerosis Registry did not receive any funding to collaborate in this study.